Sage Therapeutics (NASDAQ:SAGE) announced that its Phase 2 SURVEYOR Study has met its primary endpoint, highlighting cognitive impairments in participants with Huntington's Disease (HD) compared to healthy individuals.

The study used the HD-Cognitive Assessment Battery (HD-CAB) to measure cognition, revealing a statistically significant difference at baseline between the two groups prior to any treatment.

"Huntington’s Disease is a rare, genetic, neurodegenerative condition that greatly impacts the ability of individuals to function independently," said Laura Gault, Chief Medical Officer of Sage Therapeutics.

"The findings from the SURVEYOR Study highlight the extent of cognitive impairment associated with HD and enhance our collective understanding of this devastating disease."

Gault emphasized the critical need for treatments that address cognitive impairments in HD, a historically underrecognized aspect of the disease.